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Objective:  To  clarify  the  impact  of  off-label  use  of drug-eluting  stent  (DES)  on 5-year  outcomes.
Background:  Studies  on the  outcomes  of  on-  vs off-label  use  of DES  have  been  limited  by  the  duration  of
observation.
Methods:  We analyzed  1937  patients  from  a  multicenter  registry  that  includes  95% of patients  with
5-year  follow-up  data.  We  deﬁned  10 variables  as  off-label  indications  according  to  the manufacturer’s
instructions  for  use,  and 1665  of 1937  patients  (86.0%)  met  the  criteria  for  at least  1 off-label  indication.
Results:  At  5  years,  there  were  no  differences  in  the  rates  of death,  myocardial  infarction  (MI),  and  stent
thrombosis  between  off-label  and  on-label  use.  The  frequency  of  major  adverse  cardiac  events  (MACE),
target  lesion  revascularization  (TLR),  non-TL  but  target  vessel  revascularization  (TVR),  and  target  vessel
failure were  higher  in the  off-label  only  during  the  ﬁrst  year.  Among  the  off-label,  having  2  indications
was  associated  with  TVR  hazard  ratio  (HR)  1.62;  95%  conﬁdence  interval  (95%CI),  1.09–2.36  and  TLR  (HR,
1.90;  95%CI,  1.30–2.85).  Moreover,  having  ≥3  off-label  indications  increased  the  risk  of MACE  (HR,  1.70;
95%CI,  1.23–2.40)  compared  with on-label  use.  Thrombosis  rates  increased  with  the  number  of  off-label
indications;  it was  0.32%  with  1, 0.69% with  2, and  3.54%  with  ≥3  off-label  indications  (p <  0.001).  This
trend  was also  seen  with  other  outcomes,  except  for  non-TL  TVR.  Patients  with  ≥3  off-label  indications
had  a remarkably  different  clinical  course.
Conclusion:  Off-label  use  did  not  increase  rates  of death  and  MI  as compared  with  on-label  use,  but  the
number  of off-label  indications  inﬂuenced  outcomes  at 5 years.
3  Jap© 201
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The long-term safety and efﬁcacy of drug-eluting stents
DES) remain important topics under debate, especially with
he increased incidence of late and very late stent thromboses
irectly associated with life-threatening clinical outcomes such as
eath and myocardial infarction (MI) [1–4]. On the other hand,
iscrepancies in results from pivotal clinical trials and large-scale
egistries also affected the direction for clinicians in practice [4–7].
uch differences might be attributable to differences in patient
election. Early clinical trials included only patients who met  inclu-
ion criteria approved by the US Food and Drug Administration
FDA), i.e. on-label indications. However, in actual clinical practice
∗ Corresponding author at: 5-7-1 Fujishiro-dai, Suita 565-8565,
apan. Tel.: +81 6 6833 5012; fax: +81 6 6872 7486.
E-mail address: Shamallv8@aol.com (J. Kotani).
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ttp://dx.doi.org/10.1016/j.jjcc.2013.03.007anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
DES are routinely used for off-label indications. Off-label DES use,
which the FDA has cautioned against, can be associated with an
excessive late risk of death and MI  [8]. However, studies investi-
gating outcomes based on on- vs off-label indications in the real
world have been of short duration.
Given this context, the purpose of this study is to clarify (1) the
impact of off-label use on long-term clinical outcomes compared
with on-label (standard) use and (2) the impact of individual off-
label parameters and the number of off-label indications on the
outcome after sirolimus-eluting stent (SES) implantation during
the 5 years of observation.
Methods
Population and data collectionThis analysis used data from the CypherTM stent Japan Post-
Marketing Surveillance (J-PMS) database. J-PMS is a registry for
prospective post-marketing surveillance lasting 5 years following
vier Ltd. All rights reserved.
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least 1 off-label indication. Patients with off-label indications were
more likely to have had a previous MI,  previous PCI, multi-vessel
disease, and a lower body mass index (Table 1). Lesion character-
istics are listed in Table 2. Because label indications were mainly
Table 1
Baseline patient characteristics.
Off-label
(n = 1665)
On-label
(n = 272)
P value
Mean age, years 67.1 ± 9.9 67.9 ± 9.6 0.32
Age  ≥ 75 years 407 (24.4) 64 (23.5) 0.82
Male sex 1254 (75.3) 210 (77.2) 0.54
LVEF < 30% 55 (3.9) 6 (2.6) 0.45
BMI, kg/m2 24.0 ± 3.3 24.3 ± 3.1 0.043
Acute MI  84 (5.1) 0 (0.0) –
Recent/old MI  274 (16.5) 33 (12.4) 0.07
Stable/silent ischemia 1092 (65.6) 181 (66.5) 0.78
Unstable angina 206 (12.4) 57 (21.0) <0.001
Other 9 (0.5) 1 (0.5) 1.00
Previous MI  664 (39.9) 81 (29.8) 0.002
Previous PCI 965 (58.0) 128 (47.1) 0.001
Previous CABG 141 (8.5) 18 (6.6) 0.34
Diabetes 733 (44.0) 109 (40.1) 0.24
Requiring insulin 177 (10.6) 21 (7.7) 0.16
Dialysis 91 (5.5) 9 (3.3) 0.18
Hypertension 1155 (69.4) 200 (73.5) 0.18
Dyslipidemia 944 (56.7) 160 (58.8) 0.55
Peripheral vascular disease 111 (6.7) 14 (5.1) 0.42
Cerebrovascular disease 131 (7.9) 17 (6.3) 0.39
Family history of CAD 113 (6.8) 18 (6.6) 0.92
Current smoker 311 (18.7) 54 (19.9) 0.68
Multi-vessel disease 702 (42.2) 95 (34.9) 0.028
DAPT administration at 5 593 (36.5) 85 (31.3) 0.1052 J. Kotani et al. / Journal of
he index procedure. It was mandated by the Japanese government
s one of the conditions for regulatory approval. The details of this
rogram have been described previously [9,10]. Brieﬂy, the reg-
stry enrolled the consecutive 2050 cases of SES implantation from
eptember 2004 through September 2005 at 50 institutions across
apan. The decision to perform stent implantation was left to the
iscretion of each cardiologist participating in the registry. Angiog-
aphic follow-up is mandated at 8 months, and clinical follow-up
as scheduled annually up to 5 years. Angiographic data on 1063
f 2459 lesions were analyzed by an independent core laboratory
Cardiocore, Tokyo, Japan) and the remaining angiograms were
nalyzed by on-site quantitative coronary angiography (QCA). The
nstitutional review board at each participating center approved
he study.
eﬁnition of off-label
The manufacturer’s directions for use of the CypherTM stent
Cordis, Miami, FL, USA) state that it is indicated for “improving the
oronary luminal diameter in patients with symptomatic ischemic
isease due to discrete de novo lesions of length ≤30 mm in native
oronary arteries with a reference vessel diameter of ≥2.5 and
3.5 mm”  [11]. The following 10 conditions were deﬁned as off-
abel indications by DES manufacturer’s instructions for use: acute
yocardial infarction (acute MI), bifurcation lesions (type B/C of the
merican College of Cardiology/American Heart Association classi-
cation), ostial disease (<5 mm from oriﬁce), left main coronary
rtery, reference diameter less than 2.5 mm,  reference diame-
er greater than 3.5 mm,  lesions greater than 30 mm in length,
estenotic lesions including in-stent restenosis, bypass graft, and
hronic total occlusion.
utcome parameters
An independent safety and efﬁcacy evaluation committee adju-
icated all reported and suspected major adverse cardiac events
MACE) deﬁned as death, MI,  and target lesion revascularization
TLR) by percutaneous coronary intervention (PCI) or coronary-
rterial bypass grafting (CABG). Deaths were classiﬁed as cardiac
r non-cardiac, and death of any unidentiﬁed cause or in which a
ardiac cause could not be excluded was classiﬁed as cardiac in this
tudy. MI  was classiﬁed as Q wave or non-Q wave, and was deﬁned
s a rise in creatine kinase enzyme concentrations above twice the
pper limit normal. Re-interventions inside the implanted stent
r within 5 mm proximal or distal to the stent were classiﬁed as
LR. The deﬁnition of TLR had been registered according to the SIR-
US criteria. That is, TLR is deﬁned as any “clinically-driven” repeat
ercutaneous intervention of the target lesion or bypass surgery of
he target vessel. Clinically-driven revascularizations are those in
hich the patient has a positive functional study, ischemic electro-
ardiographic (ECG) changes at rest in a distribution consistent with
he target vessel, or ischemic symptoms, and an in-lesion diameter
tenosis ≥50% by QCA. Revascularization of a target lesion with an
n-lesion diameter stenosis ≥70% (by QCA) in the absence of the
bove-mentioned ischemic signs or symptoms is also considered
linically driven. In the absence of QCA data for relevant follow-up
ngiograms, the clinical need for revascularization is adjudicated
sing the presence or absence of ischemic signs and symptoms.
epeated PCI to the same vessel with the exception of TLR was
ounted as non-TL target vessel revascularization (TVR). Target ves-
el failure (TVF) was deﬁned as all target vessel-related events,
hich included cardiac death, MI,  thrombosis, and TVR. Deﬁnite
nd probable stent thromboses according to the Academic Research
onsortium (ARC) classiﬁcation were considered stent thrombosis
12].ology 62 (2013) 151–157
Statistical analysis
Continuous variables are expressed as means ± standard devi-
ation and categorical data are presented as frequencies. For
comparisons between groups, Fisher’s exact test or an ANOVA
test was used as appropriate. Time-to-event data are presented
as Kaplan–Meier estimates. Both TLR and MACE rates during the
follow-up period were analyzed by the Kaplan–Meier method. A
log-rank test was used for survival comparisons. Multivariable
Cox proportional hazards regression model was used by step-
wise selection process (p < 0.1). Variables for 5-year outcomes
were selected from patient background and lesion characteris-
tics; age  75 years old, male, body mass index ≥ 25, previous MI,
previous PCI, previous CABG, hypertension, dyslipidemia, dialysis,
peripheral vascular disease, cardiovascular disease, family his-
tory of coronary artery disease, diabetes, current smoking, and
multi-vessel disease. And acute MI,  bifurcation, ostial, left main
trunk, reference vessel diameter < 2.5 mm,  reference vessel diam-
eter > 3.5 mm,  length > 30 mm,  restenosis, bypass graft, and total
occlusion were used for predicting risk factors for TVF. A p-value
less than 0.05 was considered statistically signiﬁcant. Statistical
analyses were performed with the use of SAS software, version 9.1.3
(SAS Institute, Cary, NC, USA).
Results
Patient and lesion characteristics
Initially, the registry planned to enroll 2053 patients, but 3
patients with off-label use were not included due to stent delivery
failure. There were 1937 patients with complete 5-year follow-up
data available, of whom 272 had on-label indications (standard
use). The remaining 1665 patients (86.0%) met the criteria for atyear follow-up
LVEF, left ventricular ejection fraction; BMI, body mass index; MI,  myocardial infarc-
tion; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft;
CAD, coronary artery disease; DAPT, dual anti-platelet therapy.
J. Kotani et al. / Journal of Cardio
Table  2
Lesion characteristics.
Off-label
(n = 1665)
On-label
(n = 272)
P value
No. of lesions/stents 2020/2758 295/339 –
Target vessel <0.001
RCA 568 (28.1) 138 (46.8)
LAD 907 (44.9) 109 (36.9)
LCX 455 (22.5) 48 (16.3)
LMT  89 (4.4) 0 (0.0)
Graft 14 (0.7) 0 (0.0)
ACC/AHA type B2/C 1668 (82.9) 198 (67.3) <0.001
QCA data
Lesion length, mm 17.7 ± 10.7 15.4 ± 6.1 0.12
Reference diameter, mm 2.52 ± 0.62 2.88 ± 0.27 <0.001
MLD
Pre, mm 0.73 ± 0.49 0.89 ± 0.41 <0.001
Post, mm 2.21 ± 0.67 2.56 ± 0.51 <0.001
%DS
Pre, % 71.5 ± 17.2 69.3 ± 14.1 0.042
Post, % 19.7 ± 14.0 14.8 ± 11.1 <0.001
Procedural data
Direct stenting 417 (20.6) 92 (31.2) <0.001
Rotablator usage 83 (4.1) 8 (2.7) 0.33
IVUS usage 1473 (72.9) 216 (73.2) 0.94
Maximum pressure, atm 16.0 ± 3.6 16.1 ± 3.1 0.94
Stent diameter, mm 2.98 ± 0.36 3.14 ± 0.34 <0.001
Total stent length, mm 29.5 ± 15.3 23.6 ± 9.3 <0.001
No. of stents per patient 1.64 ± 0.84 1.25 ± 0.48 <0.001
No.  of stents per lesion 1.36 ± 0.62 1.15 ± 0.38 <0.001
Post dilatation 966 (47.8) 111 (37.6) 0.001
RCA, right coronary artery; LAD, left anterior descending; LCX, left circumﬂex; LMT,
left  main trunk; ACC/AHA, American College of Cardiology/American Heart Asso-
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23.3%) patients. The risk of multiple off-label indications as
compared to standard use is shown in Fig. 2. Multivariate anal-
ysis showed that having 1 or 2 off-label indications does not
increase the risk of death and MI.  However, 2 and more off-label
Table 4
Five-year outcomes in off-label indication compared to the on-label use.
Univariate analysis Multivariate analysis
Hazard ratio
(95% CI)
p-Value Hazard ratio
(95% CI)
p-Value
MACE 1.41 (1.05–1.90) 0.23 1.31 (0.98–1.77) 0.07
Death 1.19 (0.82–1.72) 0.36 1.05 (0.73–1.53) 0.79
MI  1.64 (0.71–3.80) 0.25 1.56 (0.67–3.62) 0.30
TVF  1.82 (1.28–2.58) 0.001 1.57 (1.10–2.24) 0.012
TLR  2.08 (1.21–3.60) 0.008 1.89 (1.09–3.25) 0.023
Non-TL TVR 2.19 (1.25–3.86) 0.006 1.94 (1.10–3.41) 0.022
Def./prob. thrombosis 1.23 (0.37–4.09) 0.74 1.07 (0.32–3.59) 0.91
T
C
M
riation; QCA, quantitative coronary angiography; MLD, minimal luminal diameter;
DS, percent diameter stenosis; IVUS, intravascular ultrasound.
lassiﬁed by lesion characteristics, the off-label group was  more
ikely to be complex. QCA parameters presented smaller ﬁnal min-
mal lumen diameter and greater % diameter stenosis after the
rocedure in the off-label group (p < 0.001). Also, the off-label group
ad longer stent length, smaller stent caliber, and more stents per
atient or lesion (p < 0.001). Eight months angiographic follow-
p ratio was 87.2% (1451/1665 patients) in off-label and 85.7%
233/272 patients) in on-label. There were no signiﬁcant differ-
nces (p = 0.497). This frequency was also similar in patients who
eceived TLR (91.2% and 85.7%; p = 0.6) and TVF (87.3% vs 91.2%;
 = 0.6).
requency and timing of events after stent implantation
The overall outcomes at year 5, and during year 0–1 (early
hase) and years 2–5 (late phase) for off-label and standard use
re presented in Table 3. Cumulative 5-year results showed no
ifferences in hard endpoints such as death (cardiac death, 5.0%
s 4.0%, p = 0.6; non-cardiac death, 8.6% vs 7.7%, p = 0.7), MI,  and
tent thrombosis. Revascularization-related parameters, such as
able 3
linical outcomes during 5 years of follow-up in 1937 patients.
30 days events Early (0–1 year) 
On-label Off-label p On-label Off-label 
MACE 1 (0.4) 15 (1.6) 0.25 13 (4.8) 132 (7.9) 
Death 0 (0.0) 7 (0.4) 0.60 8 (2.9) 40 (2.4) 
MI  0 (0.0) 7 (0.4) 0.60 1 (0.4) 23 (1.4) 
TVF  1 (0.4) 10 (0.6) 1.00 10 (3.7) 174 (10.5) 
TLR  0 (0.0) 3 (0.2) 1.00 4 (1.5) 79 (4.7) 
Non-TL TVR 1 (0.4) 3 (0.2) 0.45 6 (2.2) 88 (5.3) 
Def./prob. thrombosis 0 (0.0) 1 (0.1) 1.00 0 (0.0) 8 (0.5) 
ACE, major adverse cardiac event; MI,  myocardial infarction; TVF, target vessel failure; T
evascularization; Def/prob thrombosis, deﬁnite and probable stent thrombosis.logy 62 (2013) 151–157 153
the rates of MACE (p = 0.030), TLR (p = 0.007), non-TL TVR (p = 0.005),
and TVF (p = 0.001) at year 5 were higher in the off-label group, but
this trend was only seen in the early phase. There was no difference
in frequency between on- and off-label groups during years 2–5
after index (late phase). All on-label use (3/3) and 63.6% of off-label
patients (14/22) experienced stent thrombosis 1 year or more after
the index procedure (very late stent thrombosis). Table 4 shows 5-
year outcomes in the off-label and on-label use groups. Multivariate
analysis showed that the differences between the 2 groups were
seen in revascularization-related parameters such as TVF [hazard
Ratio (HR), 1.57; 95% conﬁdence interval (95%CI), 1.10–2.24], TLR
(HR, 1.89; 95%CI, 1.09–3.25), and non-TL TVR (HR, 1.94; 95%CI,
1.10–3.41) within 5 years of the index procedure.
Impact of individual off-label indications on outcomes
The frequency of each off-label indication in this study was
as follows: acute MI  (n = 84), ostial location (n = 457), left main
artery (n = 89), venous graft (n = 14), restenosis (n = 447), total
occlusion (n = 249), bifurcation (n = 694), small and large refer-
ence vessel (<2.5 mm,  n = 951 and >3.5 mm,  n = 141), and long
lesion length > 30 mm (n = 246). The impact of each off-label indi-
cation on TVF is shown in Fig. 1. Ostial lesions, small vessel with
reference diameter < 2.5 mm and large vessel with reference diam-
eter > 3.5 mm were independent risk factors for TVF.
Impact of multiple off-label indications on clinical events
There were 1665 cases of off-label use, including 634 patients
with 1 off-label indication (32.7%) and 1031 with multiple off-
label indications (2 indications: n = 579, 29.9%; 3 or more: n = 452,CI, conﬁdence interval; MACE, major adverse cardiac event; MI,  myocardial infarc-
tion; TVF, target vessel failure; TLR, target lesion revascularization; non-TL TVR,
non-target lesion but target vessel revascularization; Def./prob. thrombosis, deﬁnite
and probable stent thrombosis.
Late (2–5 years) Total (0–5 years)
p On-label Off-label p On-label Off-label p
0.08 36 (13.2) 268 (16.1) 0.24 49 (18.0) 400 (24.0) 0.030
0.53 32 (11.8) 227 (13.6) 0.29 227 (13.6) 32 (11.8) 0.44
0.24 5 (1.8) 36 (2.2) 0.73 6 (2.2) 59 (3.5) 0.36
<0.001 24 (8.8) 180 (10.8) 0.39 34 (12.5) 354 (21.3) 0.001
0.009 10 (3.7) 92 (5.5) 0.24 14 (5.1) 171 (10.3) 0.007
0.032 7 (2.6) 80 (4.8) 0.11 13 (4.8) 168 (10.1) 0.005
0.61 3 (1.1) 14 (0.8) 0.72 3 (1.1) 22 (1.3) 0.76
LR, target lesion revascularization; non-TL TVR, non-target lesion but target vessel
154 J. Kotani et al. / Journal of Cardi
Fig. 1. Off-label indications as risk factors for target vessel failure at 5 years. TVF,
target vessel failure; MI,  myocardial infarction; LMT, left main trunk; RVD, reference
vessel diameter.
Fig. 2. Number of off-label indications and the risk of adverse clinical outcomes at 5 yea
major  adverse cardiac event; MI,  myocardial infarction; TVF, target vessel failure; TLR
revascularization.ology 62 (2013) 151–157
indications was associated with TVF (HR, 1.62; 95%CI, 1.09–2.36)
and TLR (HR, 1.90; 95%CI, 1.30–2.85), and ≥3 off-label indica-
tions was  associated with a higher incidence of MACE (HR, 1.70;
95%CI, 1.23–2.40) when compared to on-label use. Although the
presence of multiple off-label indications tended to increase the
risk of revascularization-related events, this relationship was  not
observed for non-TL TVR. Patients with ≥3 off-label indications
remained on dual anti-platelet therapy (aspirin plus thienopy-
ridine) signiﬁcantly longer (mean, 941 ± 37 days) than patients
with standard use (790 ± 45 days, p = 0.012). Regarding throm-
bosis, there was  similar frequency of deﬁnite and probable stent
thromboses at year 5 between off-label and on-label use patients;
there were 22 in the off-label group (1.3%) and 3 (1.1%) in
the on-label use group (p = 0.9). In the off-label population, the
risk of thrombosis increased with the number of off-label indi-
cations (Fig. 3, p < 0.001); patients with 1, 2, and ≥3 off-label
indications had a 0.32% (2/634), 0.69% (4/579), and 3.54% (16/452)
incidence rate of thrombosis at 5 years.
Fig. 3 also presents the 5-year frequency curves of MACE, TVF,
death/MI, TLR, non-TL TVR, and deﬁnite/probable stent thrombosis
according to the number of off-label indications. Frequency curves
differed for all outcomes according to the number of off-label indi-
cations (i.e. 1, 2, and ≥3 off-label variables accumulation) except
rs as compared with standard use. HR, hazard ratio; CI, conﬁdence interval; MACE,
, target lesion revascularization; non-TL TVR, non-target lesion but target vessel
J. Kotani et al. / Journal of Cardiology 62 (2013) 151–157 155
Fig. 3. Impact of the number of off-label indications on 5-year clinical outcomes among the off-label patients. MACE, major advanced cardiac event; MI, myocardial infarction;
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pVF,  target vessel failure; TLR, target lesion revascularization; non-TL TVR, non-targ
tent  thrombosis.
on-TL TVR. Especially the subgroup with ≥3 off-label indications
howed marked difference from others.
iscussion
Previous studies have carried two types of information alter-
atively; sustainable effectiveness and safety concerns after DES
mplantation [1,2,5,13–16]. These discrepancies might be caused by
ifferences in patient selection, deﬁnition of off-label use, duration
f dual anti-platelet therapy, study design [i.e. comparison with
are metal stents (BMS), label-indication comparisons], and study
eriod among the studies. The current study includes completeion but target vessel revascularization; Def/prob thrombosis, deﬁnite and probable
data on 5 years study of follow-up duration, including dual anti-
platelet therapy status, and includes 95% of the patients registered
in a government-mandated post-marketing registry. Off-label use
of DES compared with standard use (1) did not increase the fre-
quency of death, MI,  or stent thrombosis at 5 years; (2) resulted in
twice the number of revascularization-related endpoints, both TLR
and non-TL TVR, but the difference was only seen within 1 year after
stent implantation; (3) was associated with TVF at 5 years if the
independent risk factors of small (<2.5 mm)  and large (>3.5 mm)
vessel, and ostial location were present; and (4) increased the
risk of adverse outcomes as the number of off-label indications
increased.
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Qasim et al. compared the long-term outcomes between on- and
ff-label use in 1044 consecutive patients who received DES using
 single-center database [17]. There were no signiﬁcant differences
n cardiac deaths at follow-up. The TLR rate per patient was twice
s high in the off-label patients. However, implantation of > 1 DES
er lesion and off-label DES use were not identiﬁed as risk factors
or TVR, and multivariate analysis for factors affecting MACE did
ot include off-label use.
Publications by Beohar et al. [13] and Win  et al. [14] are par-
icularly relevant to our current data. The D.E.S. cover registry by
eohar et al. includes 5541 patients treated with DES [13]. The study
ompared 3 groups: standard use (n = 2953), off-label (n = 1398),
nd untested indications (left main, ostial, bifurcation, or totally
ccluded lesions: n = 1190). Although more patients in the off-label
roup reached the composite end point (death/MI, or stent throm-
osis) at 30 days, there were no signiﬁcant differences at 1 year
mong the 3 groups. The 1-year data show differences in the rates
f mortality and reaching the composite safety endpoint in the off-
abel group, which disappeared after adjustment. Furthermore, the
umulative incidence of stent thrombosis was low (<1%) among
ll 3 groups. The Evaluation of Drug-Eluting Stents and Ischemic
vents (EVENT) registry compared 1817 patients (54.7%) with at
east 1 off-label indication and 1506 patients with on-label indi-
ations treated with DES [14]. During the index hospitalization,
he composite clinical outcome (death, MI,  or TVR) occurred in
0.9% of the off-label patients and 5.0% of the on-label patients.
he event rate was higher in the off-label group (17.5%) com-
ared with the on-label (8.9%) group. The report noted similar
ortality but a higher risk of MI,  stent thrombosis, and TVR in
he off-label group. This study also investigated the predictors of
eath or MI  and TVR at discharge, and death or MI  and TLR at 6
nd 12 months. Long stent length and low ejection fraction were
isk factors for reaching the composite outcome throughout the 3
ollow-up periods. The authors stressed that the events detected
uring follow-up occurred despite more than 75% use of aspirin
nd clopidogrel. These ﬁndings were compatible with our current
tudy. The frequency of each individual endpoint, such as death
r MI,  was similar in both groups; revascularization-related event
ates were higher in the off-label group at 1 year of follow-up.
eanwhile, the EVENT registry has shown the risk of thrombosis
n off-label use. This was different from our result. The EVENT reg-
stry compared the frequency of stent thrombosis between label
ndications. The frequency of stent thrombosis of EVENT registry
as 0.4% vs 0% at discharge, 1.2% vs 0.4% at 6 months (p = 0.04),
nd 1.6% and 0.9% at 12 months (p = 0.05). The authors described
hat the differences narrowed between in-hospital discharge and 1
ear follow-up. The deﬁnition of off-label in EVENT registry was not
imilar to the current study. For example, they included in off-label
ong stent ≥36 mm,  lower ejection fraction ≤25%, creatine kinase
B > x3 (moreover, high incidence of peril-procedural acute MI  was
bserved in off-label indication), etc. Iakovou et al. showed that
he stent length (1 mm increase) and left ventricle ejection frac-
ion (10% decreases) were independent predictors for early stent
hrombosis [18]. Several other differences were observed between
he present study and the EVENT registry. First, absolute frequency
f thrombosis was different. Accumulation of thrombosis through
 years in the current study (2.4%) was still lower than the 1-year
esult of the EVENT registry (2.5%). This type of trend, i.e. Japanese
ata vs foreign countries, has been well known [19]. This might
e related to procedural factors, such as intravascular ultrasound
IVUS) usage, because the main cause of early stent failure has been
eported as a mechanical problem. The second difference is deﬁni-
ion and number of off-label indications. As we mentioned above,
he EVENT registry involved more risk factors for stent thrombo-
is than the current study [18,20]. We  are showing that multiple
umbers of off-label indications are associated with frequency ofology 62 (2013) 151–157
thrombosis. The EVENT registry would have involved more off-label
indications than the current study (although they did not mention
this). And the third is patient number. The distribution of patients
between off-label and on-label in the current study was not suit-
able for statistical analysis (this was caused by consecutive study
design). Also, the overall number was  different between the current
paper and the EVENT registry. Finally, the numbers in both stud-
ies were too small to discuss stent thrombosis. These might have
affected the statistical results.
We found that 3 out of 10 off-label indications (i.e. ostial
location, small vessel < 2.5 mm,  and large vessel > 3.5 mm)  were
independent risk factors for TVF at 5 years. Lesions with ostial loca-
tion and small reference diameter have been previously implicated
as the risks of restenosis after SES implantation [21]. Regarding
large reference vessel, there was  no clear explanation. In this
group, 73.8% (107/145) received IVUS-guided stent implantation.
However, aggressive post-dilatation might affect the structural
quality. Post dilation by > 3.5 mm balloon for achievement of com-
plete attachment to the vessel wall might be destroying the
DES component. The mean reference diameter of this group was
3.88 ± 0.36 mm.
On the other hand, small vessel diameter and ostial lesion have
been recognized as high risk for restenosis since the BMS  era. It is
intuitive that the absolute reduction in TVR by DES as compared
with BMS  might be substantially larger in more complex lesions
outside of the on-label indications for DES that carry a high risk of
restenosis. Marroquin et al. [15] compared stent design (i.e. DES
and BMS) and label indication and found that, in general, off-label
use was  associated with worse clinical outcomes than was  standard
use. Speciﬁcally, the 1-year event rates of death and repeat revascu-
larization are similar to those reported by Beohar et al. [13] and Win
et al. [14], as well as our current study. Moreover, the study reported
that off-label use of BMS  also results in increased ischemic compli-
cations as compared with standard BMS  use [15]. Patients treated
with DES had signiﬁcantly lower rates of repeat revascularization
than did patients treated with BMS. There was no increased risk of
death or MI.  This study demonstrated that the use of DES for off-
label indications is more effective than the use of BMS  in reducing
the need for repeat revascularization [15]. These ﬁndings suggest
that the overall poorer outcome with off-label use is most likely
related to patient or lesion characteristics, rather than a speciﬁc
shortcoming of DES. This may  explain why the use of DES for off-
label indications is as safe as, and more effective than, the use of
BMS  for similar indications.
Rao et al. examined the frequency of DES use in off-label sit-
uations (acute ST-elevation MI,  in-stent restenosis, bypass graft,
and chronic total occlusion) and compared the in-hospital out-
comes after implantation of DES for each off-label indication to
rates expected from a validated model [22]. Out of 408,033 DES
procedures, 24.1% were for off-label indications. The rates of in-
hospital adverse events were lower than those predicted by the
ACCNCDR (American College of Cardiology National Cardiovascular
Data Registry) mortality model [23] for the 4 off-label indications
studied. The data suggest that patient selection for off-label DES
use appears to be safe and appropriate. DES implantation for these
parameters, such as acute ST-elevation MI  and total occlusion, was
also not predicted in our current study for TVF. However, since our
current study emphasizes the importance of the number of off-
label indications and predicts 3 speciﬁc off-label indications as risk
factors for TVF, it might have been inadequate just to assess all 4
off-label situations.
In actual clinical practice, the off-label group represents a
patient population with more advanced and less responsive coro-
nary artery disease. They may  inherently have less acute and
long-term beneﬁt than patients with on-label indications, but once
the decision for catheter-based coronary intervention has been
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ade, DES will probably be the best choice for such patients in most
nstances. Therefore, prior to this decision, alternative treatment
trategies, e.g. bypass surgery, should be given serious consid-
ration. Our current data provide new information, such as the
ong-term outcomes after off-label DES use, and the impact of the
umber of off-label indications on outcomes. Patients with more
han 3 off-label indications might have a different long-term clin-
cal course, despite a longer course of dual anti-platelet therapy.
ur ﬁndings also help explain the seemingly conﬂicting results
f previous studies; long-term outcomes including very late stent
hrombosis would not be reduced by prolonged dual anti-platelet
herapy [19,24]. Pre-PCI lesion complexity as deﬁned by the SYN-
AX score is positively correlated with the number of events during
ong-term follow-up [25]. Multiple off-label variables accumula-
ion also contributes to lesion complexity.
There are some limitations to our study. First, our study was
ased on an observational registry; it was not a randomized trial.
his might lead to the differences in patient characteristics. How-
ver, multiple off-label lesion subsets itself might reﬂect advanced
isease on a vessel or patient level. Multivariate analysis did not
nly reveal TLR, but also non-TL TVR, as occurring more frequently
hen compared to the on-label population at 5 years of follow-up.
The on-label population contained relatively few patients. How-
ver we not only investigated the differences between on-label and
ff-label patients, but also provided new information on various
ff-label subsets. Another limitation of our study was  the use of
rst-generation DES. Although SES are no longer on the market,
his model has been used for several comparable trials. Since it has
een suggested that lesion complexity and outcomes after PCI with
ES would not be dramatically altered by evolving stent design, our
urrent ﬁndings would be applicable to newer stents.
onclusion
Off-label use of DES, as compared with standard use, did not
ncrease the rates of death and MI,  and was associated with more
evascularization-related events only within the ﬁrst year during
 years of observation. However, the presence of multiple off-label
ndications, especially 3 or more, inﬂuenced long-term outcomes
fter DES.
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